Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb;95(2):320-3.
doi: 10.3324/haematol.2009.010355. Epub 2009 Dec 16.

Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1

Doris Steinemann  1 , Larissa Arning, Inka Praulich, Manfred Stuhrmann, Henrik Hasle, Jan Stary, Brigitte Schlegelberger, Charlotte M Niemeyer, Christian Flotho
Affiliations

Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1

Doris Steinemann et al. Haematologica. 2010 Feb.

Abstract

Children with neurofibromatosis type 1 (NF-1), being constitutionally deficient for one allele of the NF1 gene, are at greatly increased risk of juvenile myelomonocytic leukemia (JMML). NF1 is a negative regulator of RAS pathway activity, which has a central role in JMML. To further clarify the role of biallelic NF1 gene inactivation in the pathogenesis of JMML, we investigated the somatic NF1 lesion in 10 samples from children with JMML/NF-1. We report that two-thirds of somatic events involved loss of heterozygosity (LOH) at the NF1 locus, predominantly caused by segmental uniparental disomy of large parts of chromosome arm 17q. One-third of leukemias showed compound-heterozygous NF1-inactivating mutations. A minority of cases exhibited somatic interstitial deletions. The findings reinforce the emerging role of somatic mitotic recombination as a leukemogenic mechanism. In addition, they support the concept that biallelic NF1 inactivation in hematopoietic progenitor cells is required for transformation to JMML in children with NF-1.

PubMed Disclaimer

Comment in

  • Molecular basis of juvenile myelomonocytic leukemia.
    de Vries AC, Zwaan CM, van den Heuvel-Eibrink MM. de Vries AC, et al. Haematologica. 2010 Feb;95(2):179-82. doi: 10.3324/haematol.2009.016865. Haematologica. 2010. PMID: 20139388 Free PMC article. No abstract available.

References

    1. Niemeyer CM, Locatelli F. Chronic myelo-proliferative disorders. In: Pui CH, editor. Childhood Leukemia. New York: Cambridge University Press; 2006. pp. 571–98.
    1. Flotho C, Kratz CP, Niemeyer CM. Targeting RAS signaling pathways in juvenile myelomonocytic leukemia. Curr Drug Targets. 2007;8(6):715–25. - PubMed
    1. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature. 1993;366(6456):643–54. - PubMed
    1. Side L, Taylor B, Cayouette M, Conner E, Thompson P, Luce M, et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med. 1997;336(24):1713–20. - PubMed
    1. Flotho C, Steinemann D, Mullighan CG, Neale G, Mayer K, Kratz CP, et al. Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11. Oncogene. 2007;26(39):5816–21. - PubMed

Publication types

Substances